RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2023 · 62 positions · Total reported value $6.40B · Top-10 concentration 60.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2023 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 62 equity positions with a combined reported value of $6.40B. The filing implies a focused portfolio: its ten largest positions account for 60.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2023 were ASND ($1.27B), IMGN ($704.21M), PCVX ($495.57M). By sector, the heaviest allocations are Health Care 69.5%, Consumer Discretionary 1.3%. Versus the prior quarter, allocation shifted toward Other (+5.1pp) and away from Health Care (-4.6pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 80% of names.

The largest new positions opened in Q4 2023 were CCCC ($27.56M), GPCR ($19.84M), ARVN ($17.34M).

Of the 11 positions fully exited versus the prior quarter, the largest were COGT ($62.56M), SLNO ($36.56M), VRDN ($30.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2023)

  • CCCC C4 THERAPEUTICS INC · $27.56M
  • GPCR STRUCTURE THERAPEUTICS INC · $19.84M
  • ARVN ARVINAS INC · $17.34M
  • HARP HARPOON THERAPEUTICS INC · $17.05M
  • SABS SAB BIOTHERAPEUTICS INC · $1.63M

Fully Exited (vs previous quarter)

  • COGT COGENT BIOSCIENCES INC · prev qtr: $62.56M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $36.56M
  • VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $30.80M · history
  • ACRS ACLARIS THERAPEUTICS INC · prev qtr: $30.13M · history
  • EYPT EYEPOINT INC · prev qtr: $26.93M
  • CELC CELCUITY INC · prev qtr: $12.80M
  • NKTR NEKTAR THERAPEUTICS · prev qtr: $11.14M
  • TALS TALARIS THERAPEUTICS INC · prev qtr: $6.75M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

Sector Allocation

Health Care 69.5%
Materials 0.0%
Other 28.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.11M $1.27B 19.88%
19.88%
Reduce
2 23.75M $704.21M 11.00%
11.00%
Add
3 7.89M $495.57M 7.74%
7.74%
Hold
4 6.26M $376.95M 5.89%
5.89%
Hold
5 5.33M $245.04M 3.83%
3.83%
Reduce
6 8.26M $187.01M 2.92%
2.92%
Hold
7 4.72M $179.52M 2.80%
2.80%
Hold
8 6.94M $163.92M 2.56%
2.56%
Hold
9 532.89K $137.90M 2.15%
2.15%
Hold
10 3.40M $137.26M 2.14%
2.14%
Add
11 11.42M $127.53M 1.99%
1.99%
Hold
12 6.32M $125.60M 1.96%
1.96%
Hold
13 7.81M $114.02M 1.78%
1.78%
Hold
14 5.55M $113.75M 1.78%
1.78%
Hold
15 7.24M $100.22M 1.56%
1.56%
Hold
16 9.17M $98.35M 1.54%
1.54%
Hold
17 46.20M $97.49M 1.52%
1.52%
Hold
18 5.96M $93.99M 1.47%
1.47%
Hold
19 4.91M $93.58M 1.46%
1.46%
Add
20 18.20M $91.92M 1.44%
Form 4 · 1 →
1.44%
Add
21 7.86M $87.84M 1.37%
1.37%
Reduce
22 4.16M $84.35M 1.32%
1.32%
Hold
23 2.55M $84.20M 1.31%
1.31%
Reduce
24 1.00M $79.59M 1.24%
1.24%
Hold
25 11.61M $78.37M 1.22%
1.22%
Hold
26 6.81M $62.10M 0.97%
0.97%
Hold
27 14.93M $57.34M 0.90%
0.90%
Hold
28 8.13M $55.30M 0.86%
0.86%
Hold
29 1.98M $55.26M 0.86%
0.86%
Hold
30 9.46M $51.84M 0.81%
0.81%
Hold
31 7.81M $51.51M 0.81%
0.81%
Hold
32 22.75M $51.18M 0.80%
Form 4 · 1 →
0.80%
Hold
33 4.42M $48.37M 0.76%
0.76%
Hold
34 204.50K $47.32M 0.74%
0.74%
Hold
35 3.08M $46.25M 0.72%
0.72%
Add
36 4.05M $38.99M 0.61%
0.61%
Add
37 13.15M $35.51M 0.56%
Form 4 · 4 →
0.56%
Hold
38 18.47M $32.70M 0.51%
0.51%
Hold
39 5.59M $32.41M 0.51%
0.51%
Hold
40 2.12M $29.37M 0.46%
0.46%
Hold
41 4.88M $27.56M 0.43%
0.43%
New
42 3.18M $27.33M 0.43%
0.43%
Hold
43 6.14M $23.72M 0.37%
0.37%
Hold
44 4.81M $23.67M 0.37%
0.37%
Hold
45 1.28M $23.20M 0.36%
0.36%
Reduce
46 2.03M $22.30M 0.35%
0.35%
Add
47 2.45M $22.21M 0.35%
0.35%
Reduce
48 3.43M $21.04M 0.33%
0.33%
Hold
49 486.83K $19.84M 0.31%
0.31%
New
50 5.51M $17.84M 0.28%
0.28%
Reduce

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2023-Q4?

In its 2023-Q4 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 62 equity positions worth $6.40B in aggregate; its largest disclosed positions were ASND ($1.27B), IMGN ($704.21M), PCVX ($495.57M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $6.40B of long equity holdings across 62 positions as of 2023-Q4. Top-10 holdings account for 60.9% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →